Booster dose

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern

Retrieved on: 
Wednesday, May 5, 2021
Health, Infectious diseases, Genetics, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Nucleic acids, Branches of biology, COVID-19 vaccines, Clinical trials, Vaccination, RNA vaccines, RNA, Moderna COVID-19 vaccine, Booster dose, Messenger RNA, Vaccine, Lineage B.1.351, the Moderna COVID-19 Vaccine, Moderna, THE MODERNA COVID-19 VACCINE, MODERNA

A booster dose of mRNA-1273.351, the Company\xe2\x80\x99s strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant of concern than a booster dose of mRNA-1273.

Key Points: 
  • A booster dose of mRNA-1273.351, the Company\xe2\x80\x99s strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant of concern than a booster dose of mRNA-1273.
  • We are encouraged by these new data, which reinforce our confidence that our booster strategy should be protective against these newly detected variants.
  • We look forward to sharing data on our multivalent booster candidate, mRNA-1273.211, which combines mRNA-1273 and mRNA-1273.351 in a single vaccine, when available.
  • Today\xe2\x80\x99s update includes preliminary data two weeks following administration of a booster dose of mRNA-1273 or mRNA-1273.351.

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study

Retrieved on: 
Tuesday, May 4, 2021
Life sciences, Vaccines, Biotechnology, Health sciences, Medical research, Vaxart, Norovirus, Booster dose, Booster

Vaxart\xe2\x80\x99s VP1-based bivalent oral tablet vaccine candidate targets the norovirus GI.1 Norwalk and GII.4 Sydney strains, which are the predominant strains affecting humans.\nThe booster regimen trial is the second of four Vaxart norovirus trials that are ongoing or are planned for 2021.

Key Points: 
  • Vaxart\xe2\x80\x99s VP1-based bivalent oral tablet vaccine candidate targets the norovirus GI.1 Norwalk and GII.4 Sydney strains, which are the predominant strains affecting humans.\nThe booster regimen trial is the second of four Vaxart norovirus trials that are ongoing or are planned for 2021.
  • Vaxart is currently administering a second booster dose to a subset of subjects who had participated in the prior Phase 1b bivalent study.
  • The Company is also scheduled to initiate an age escalation trial in subjects over 65 years old and plans to launch a Phase 2 challenge study later this year.\nThe Phase 1b study is designed to enroll 30 subjects aged 18 to 55 years old.
  • Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.\n'

ShareRing Joins Good Health Pass Collaborative as Contributor

Retrieved on: 
Sunday, April 11, 2021
Medical specialties, Vaccination, Medicine, Clinical medicine, Zoonoses, Animal virology, Booster dose, Cowpox, Vaccine

"The COVID-19 virus is unlikely to go away anytime soon as many scientists project it will become endemic, possibly requiring yearly boosters," he explained.

Key Points: 
  • "The COVID-19 virus is unlikely to go away anytime soon as many scientists project it will become endemic, possibly requiring yearly boosters," he explained.
  • "The need for digital health pass systems may thus likely only grow as more people get vaccinated and then possibly need subsequent booster shots.
  • The Good Health Pass Collaborative is already doing yeoman\'s work to help the world to quickly find its collective voice on a crucial technological solution.
  • "\n"We are delighted to welcome ShareRing to the Good Health Pass Collaborative," said head of advocacy and communications, Ethan Veneklasen.